Vijaya Diagnostic Share Price Up 3.3% to Rs 1,355 on Emkay Buy — Q4 FY26 PAT +37.5% to Rs 47.93 Cr, Revenue +26.6%
- June 25, 2026
- Posted by: Neeraj Pandey
- Category: News
Vijaya Diagnostic share price Rs 1,355.80 (+3.29%), prev close Rs 1,312.60, high Rs 1,375.30. Emkay reiterates Buy. Q4 FY26: PAT Rs 47.93 Cr (+37.5%), revenue Rs 219.38 Cr (+26.6%).
The Vijaya Diagnostic share price is trading at Rs 1,355.80 on NSE today, up approximately 3.29% from the previous close of Rs 1,312.60, touching an intraday high of Rs 1,375.30, after Emkay Global Financial Services reiterated its Buy rating on the stock citing strong and broad-based growth momentum across key markets. The Vijaya Diagnostic share price has been on a structural uptrend supported by sustained double-digit revenue growth and earnings acceleration. Ankit Jaiswal, Senior Research Analyst at Univest covers the Emkay Buy thesis and what is driving the Vijaya Diagnostic share price to near its 52-week high of Rs 1,427.80.
Emkay’s Buy reiteration on the Vijaya Diagnostic share price is grounded in the company’s consistently strong operational delivery across its core and emerging geographies. South India’s leading integrated diagnostics chain has been expanding its hub network beyond its stronghold of Hyderabad, Andhra Pradesh, and Telangana into newer markets including Pune and other non-core geographies, and the growth from these expansion markets is now becoming visible in the numbers. Emkay has previously cited a management target of approximately 15% sales CAGR over FY25-28, with an expectation of 18% sales CAGR over the longer term, backed by timely commissioning of new diagnostic hubs in non-core geographies. The Vijaya Diagnostic share price at Rs 1,355 reflects the market’s recognition that this execution is on track.
Click Here – Get Free Investment Predictions
Vijaya Diagnostic Share Price and Financial Performance
| Period | Revenue (Rs Cr) | YoY Growth | PAT (Rs Cr) | YoY Growth |
|---|---|---|---|---|
| Q4 FY26 | 219.38 | +26.63% | 47.93 | +37.49% |
| Q3 FY26 | 205.21 | +21.44% | 43.18 | +22.81% |
| Q2 FY26 | 208.00 | +14% | 43.28 | +3.2% |
| Q1 FY26 | 188.00 | +20% | 38.34 | +22% |
| FY26 Full Year | 814.20 | +19.49% | 172.98 | +20.30% |
What Is Vijaya Diagnostic? The Business Behind the Emkay Buy Call
Track Vijaya Diagnostic Share Price Live on Univest Screener
Vijaya Diagnostic Centre Limited is one of India’s largest integrated diagnostic chains, with a concentrated presence across approximately 150+ centres in Hyderabad, Visakhapatnam, and tier-2 cities of Andhra Pradesh and Telangana. The company offers comprehensive diagnostic services spanning basic pathology and blood tests to high-end radiology including MRI, CT scans, PET-CT imaging, and ultrasound. Premium radiology services drive approximately 40% of total revenue and carry higher margins, giving Vijaya a more favourable revenue mix than pure-play pathology chains. The corporate wellness segment , growing at approximately 25% annually , serves the rapidly expanding IT workforce concentrated in Hyderabad. The Vijaya Diagnostic share price premium over smaller diagnostic chains reflects this superior revenue mix and the strong brand moat built over decades in South India.
The investment case for the Vijaya Diagnostic share price that Emkay is reinforcing today is built on three pillars. First, non-core geography expansion: the company is actively commissioning new diagnostic hubs in cities like Pune where it previously had limited presence, diversifying revenue sources and creating a second growth runway beyond the core South Indian market. Second, earnings quality: with EBITDA margin around 40% (among the highest in Indian diagnostics), Vijaya converts strong revenue growth efficiently into bottom-line growth , Q4 FY26 demonstrated this with PAT growing 37.5% on 26.6% revenue growth. Third, structural sector tailwinds: rising health consciousness, expansion of corporate wellness programmes, and increasing radiology penetration in the Indian diagnostics market (currently underpenetrated vs developed markets) all support a multi-year growth runway for the Vijaya Diagnostic share price.
Conclusion: Vijaya Diagnostic Share Price Today
The Vijaya Diagnostic share price at Rs 1,355.80 (+3.29%) is responding positively to Emkay’s Buy reiteration, which is anchored in Q4 FY26 results showing 37.5% PAT growth and 26.6% revenue growth. The Vijaya Diagnostic share price has strong fundamental support from management’s 15% sales CAGR guidance, high EBITDA margins (~40%), and expansion into non-core geographies. Track the Vijaya Diagnostic share price live on Univest. Consult a SEBI-registered financial advisor before investing.
Download the Univest iOS App or Univest Android App to track the Vijaya Diagnostic share price and healthcare sector live on Univest.
Disclaimer: This article is for educational and informational purposes only. Stock data sourced from NSE/BSE. Analyst ratings and targets sourced from public disclosures. This does not constitute investment advice. Investments in securities are subject to market risk. Consult a SEBI-registered financial advisor before investing. Univest (Uniresearch Global Pvt Ltd, SEBI RA INH000013776).
Frequently Asked Questions
What is Vijaya Diagnostic share price today?
Ans. Vijaya Diagnostic share price (NSE: VIJAYA) is Rs 1,355.80 today, up approximately 3.29% from the previous close of Rs 1,312.60. The stock touched an intraday high of Rs 1,375.30. The move follows Emkay Global’s Buy reiteration citing strong growth across key markets. The 52-week high of Vijaya Diagnostic share price is Rs 1,427.80.
Why did Emkay reiterate Buy on Vijaya Diagnostic?
Ans. Emkay Global reiterated its Buy rating on Vijaya Diagnostic on the basis of strong and broad-based growth momentum: Q4 FY26 revenue grew 26.63% to Rs 219.38 crore and PAT grew 37.49% to Rs 47.93 crore. Emkay cites management’s guidance of approximately 15% sales CAGR over FY25-28, expansion into non-core geographies including Pune, timely commissioning of new diagnostic hubs, and operating leverage from a high EBITDA margin base (~40%).
What are Vijaya Diagnostic’s Q4 FY26 results?
Ans. Vijaya Diagnostic Centre reported Q4 FY26 standalone net profit of Rs 47.93 crore, up 37.49% year-on-year from Rs 34.86 crore. Revenue from operations rose 26.63% to Rs 219.38 crore from Rs 173.24 crore in Q4 FY25. For full year FY26: revenue Rs 814.20 crore (+19.49% YoY), PAT Rs 172.98 crore (+20.30% YoY). EBITDA margin remains strong at approximately 40%.
What does Vijaya Diagnostic do?
Ans. Vijaya Diagnostic Centre is South India’s largest integrated diagnostic chain with 150+ centres primarily in Hyderabad, Visakhapatnam, and tier-2 cities of Andhra Pradesh and Telangana. The company provides a full spectrum of diagnostic services including pathology, radiology (MRI, CT, PET-CT), ultrasound, and corporate wellness testing. Premium radiology contributes approximately 40% of revenue. The company serves pathology labs, hospitals, individual patients, and corporate clients. It is now expanding into non-core geographies including Pune.
What is the target price for Vijaya Diagnostic share price?
Ans. Emkay Global has a Buy rating on Vijaya Diagnostic with a DCF-based target. The consensus from approximately 9 analysts has an average 12-month target price of approximately Rs 1,175, with a high estimate of Rs 1,300. At the current Vijaya Diagnostic share price of Rs 1,355, the stock has outperformed consensus targets, reflecting the strong fundamental delivery. Track live Vijaya Diagnostic share price and updated analyst targets on the Univest Screener.
What is Vijaya Diagnostic’s growth strategy?
Ans. Vijaya Diagnostic’s growth strategy rests on three pillars: (1) deepening penetration in its core South Indian markets (Hyderabad, AP, Telangana) through additional centres and services; (2) geographic expansion into non-core markets including Pune and other Tier-1 cities outside South India; and (3) premium segment growth , expanding MRI, CT, PET-CT, and corporate wellness revenue that carry significantly higher margins than routine pathology. Management has guided for approximately 15% sales CAGR over FY25-28.
Is Vijaya Diagnostic share price a good buy?
Ans. Emkay Global maintains a Buy rating on Vijaya Diagnostic, backed by 15% sales CAGR guidance, 40% EBITDA margins, and strong Q4 FY26 results. The 52-week range is Rs 813.15 to Rs 1,427.80; the stock at Rs 1,355 is near its 52-week high. At approximately 75x trailing P/E, it is a premium valuation that requires consistent delivery. Revenue growth of 17-20% forecast over the next 3 years supports the valuation. Consult a SEBI-registered financial advisor before investing.
What is the 52-week high of Vijaya Diagnostic share price?
Ans. The 52-week high of Vijaya Diagnostic share price is Rs 1,427.80. The 52-week low is Rs 813.15 (approximately Rs 848 on BSE). The current Vijaya Diagnostic share price of Rs 1,355.80 is approximately 4.9% below the 52-week high, suggesting the stock is in a strong uptrend and approaching resistance near its prior peak.
